Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations

Zettler, C. M., De Silva, D. L., Blinder, V. S., Robson, M. E., & Elkin, E. B. (2024). Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations. JAMA Network Open, 7(1), e2350067. https://doi.org/10.1001/jamanetworkopen.2023.50067
Authors:
Christina M Zettler
Dilanka L De Silva
Victoria S Blinder
Mark E Robson
Elena B Elkin
Affiliated Authors:
Elena B Elkin
Subjects:
Publication Type:
Article
Unique ID:
10.1001/jamanetworkopen.2023.50067
PMID:
Publication Date:
Data Source:
PubMed

Record Created: